Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $22.3 million.

  • Catalyst Pharmaceuticals' Share-based Compensation rose 28.16% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year increase of 13.87%. This contributed to the annual value of $22.3 million for FY2024, which is 56.15% up from last year.
  • According to the latest figures from FY2024, Catalyst Pharmaceuticals' Share-based Compensation is $22.3 million, which was up 56.15% from $14.2 million recorded in FY2023.
  • In the past 5 years, Catalyst Pharmaceuticals' Share-based Compensation ranged from a high of $22.3 million in FY2024 and a low of $6.1 million during FY2021.
  • Its 3-year average for Share-based Compensation is $14.8 million, with a median of $14.2 million in 2023.
  • Its Share-based Compensation has fluctuated over the past 5 years, first declined by 3.00% in 2021, then surged by 80.22% in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Share-based Compensation (Yearly) stood at $6.3 million in 2020, then declined by 3.00% to $6.1 million in 2021, then soared by 30.20% to $7.9 million in 2022, then skyrocketed by 80.22% to $14.2 million in 2023, then spiked by 56.15% to $22.3 million in 2024.